Chemotherapy and Immunotherapy for the Urologist and Advanced Practice Provider Webcast (2021)

Interdisciplinary review of new and historical systemic treatments for prostate, bladder, and kidney cancer. Concept of IO and CPI will be reviewed. Most recent NCCN guidelines and the studies that shaped these will be reviewed for each tumor type. At the end of the didactic, the audience will be introduced to various cases and asked to respond to best care.

 

ACKNOWLEDGEMENTS

Support provided by independent educational grants from Amgen, Astellas, AstraZeneca, Bristol Myers Squibb, Janssen Biotech, Inc., administered by Janssen Scientific Affairs, LLC, Merck, Pfizer, Inc. and Sanofi Genzyme.

Target Audience

  • Urologists
  • Residents
  • Advanced Practice Providers (Nurse Practitioners and Physician Assistants)

Learning Objectives

At the conclusion of the activity, participants will be able to:

  1. Explain the mechanism of checkpoint inhibitors.
  2. Describe historical and novel treatments for systemic prostate cancer, including their mechanism, efficacy, side effects, and where they fit in the disease map.
  3. Describe historical and novel treatments for systemic bladder cancer, including their mechanism, efficacy, side effects, and where they fit in the disease map.
  4. Describe historical and novel treatments for systemic kidney cancer, including their mechanism, efficacy, side effects, and where they fit in the disease map.
Course summary
Available credit: 
  • 2.00 AMA PRA Category 1 Credit™
  • 2.00 Non-Physician Participation
Course opens: 
05/25/2021
Course expires: 
03/01/2022
Rating: 
0

Education Council Disclosures

PDF icon Education Council Disclosures 2021

COI Review Work Group Disclosures

PDF icon COI Review Work Group Disclosures 2021

All relevant financial relationships have been mitigated. 

AUA Office of Education Staff has nothing to disclose.

Course Director(s)

Costas Lallas, MD

has no relevant financial relationships to disclose at this time.
Faculty(s)

Anne Lizardi-Calvaresi, MD

has a financial relationship (Other) with Genome Dx;.
has a financial relationship (Independent contractor) with Tolmar;.
has a financial relationship (Other) with cysview;.
has a financial relationship (Independent contractor) with Janssen;.

Edouard Trabulsi, MD,MBA

has a financial relationship (Independent contractor) with Janssen;.
has a financial relationship (Independent contractor) with Pfizer ;.
has a financial relationship (Independent contractor) with Astellas;.
has a financial relationship (Independent contractor) with GenomeDx;.

METHOD OF PARTICIPATION: 

Learners will participate in this online educational activity by viewing the webcast and/or listening to the podcast and completing the post-test and evaluation. To claim CME credit for this enduring material, learners must complete the post-test, passing with 80% accuracy, and submit the program evaluation.

Estimated time to complete this activity: 2.00 hours

Release Date: May, 2021
Expiration Date: March, 2022

ACCREDITATION: 

The American Urological Association (AUA) is accredited by the Accreditation Council for Continuing Medical Education (ACCME) to provide continuing medical education for physicians.

CREDIT DESIGNATION: 

The American Urological Association designates this enduring material for a maximum of 2.00 AMA PRA Category 1 Credits™. Physicians should claim only the credit commensurate with the extent of their participation in the activity.

OTHER LEARNERS: 

The AUA is not accredited to offer credit to participants who are not MDs or DOs. However, the AUA will issue documentation of participation that states that the activity was certified for AMA PRA Category 1 Credit™.

EVIDENCE BASED CONTENT: 

It is the policy of the AUA to ensure that the content contained in this CME activity is valid, fair, balanced, scientifically rigorous, and free of commercial bias.

AUA DISCLOSURE POLICY: 

All persons in a position to control the content of an educational activity (i.e., activity planners, presenters, authors) are required to disclose to the provider any relevant financial relationships with any commercial interest. The AUA must determine if the individual’s relationships may influence the educational content and resolve any conflicts of interest prior to the commencement of the educational activity. The intent of this disclosure is not to prevent individuals with relevant financial relationships from participating, but rather to provide learners information with which they can make their own judgments.

RESOLUTION OF IDENTIFIED CONFLICT OF INTEREST: 

All disclosures will be reviewed by the AUA Conflict of Interest (COI) Review Work Group for identification of conflicts of interest. The AUA COI Review Work Group, working with the program directors and/or editors, will document the mechanism(s) for management and resolution of the conflict of interest and final approval of the activity will be documented prior to implementation. Any of the mechanisms below can/will be used to resolve conflict of interest:

  • Peer review for valid, evidence-based content of all materials associated with an educational activity by the course/program director, editor, and/or AUA COI Review Work Group.
  • Limit content to evidence with no recommendations
  • Introduction of a debate format with an unbiased moderator (point-counterpoint)
  • Inclusion of moderated panel discussion
  • Publication of a parallel or rebuttal article for an article that is felt to be biased
  • Limit equipment representatives to providing logistics and operation support only in procedural demonstrations
  • Divestiture of the relationship by faculty

OFF-LABEL OR UNAPPROVED USE OF DRUGS OR DEVICES: 

The audience is advised that this continuing medical education activity may contain reference(s) to off-label or unapproved uses of drugs or devices. Please consult the prescribing information for full disclosure of approved uses.

Available Credit

  • 2.00 AMA PRA Category 1 Credit™
  • 2.00 Non-Physician Participation
Please login or register to take this course.